Jaguar Health to Host Investor Webcast on August 13th

Jaguar Health, Inc. (NASDAQ: JAGX) will conduct an investor webcast on Tuesday, August 13, 2024, at 8:30 a.m. Eastern. The webcast will review the company's second-quarter 2024 financials and provide corporate updates. Jaguar plans to file its Earnings Report for the quarter ended June 30, 2024, on Form 10-Q on the same day.

The Phase 3 OnTarget Clinical Trial examined the efficacy of crofelemer in preventing cancer therapy-related diarrhea (CTD). This study is unique as it uses patient-reported outcomes to address CTD. The trial covered 10 tumor types and involved multiple standard chemotherapies. Many patients opted to extend their participation for an additional 12 weeks.

Crofelemer, derived from the Croton lechleri tree, is FDA-approved and was developed under sustainable practices. Jaguar Health, through its subsidiaries, focuses on developing plant-based medicines for gastrointestinal distress and other conditions in humans and animals.